GGHC
ARCT icon

Gilder Gagnon Howe & Co’s Arcturus Therapeutics ARCT Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,541
Closed -$275K – 272
2014
Q3 		$275K Sell
2,541
-3
-0.1% -$391 ﹤0.01% 243
2014
Q2 		$308K Buy
+2,544
New +$307K ﹤0.01% 256

Other funds holding ARCT

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Gilder Gagnon Howe & Co's ARCT Position: Q4 2014 in Review

Gilder Gagnon Howe & Co sold out of Arcturus Therapeutics (ARCT) in Q4 2014, closing a stake of 2,541 shares — an estimated $275K sold.

Gilder Gagnon Howe & Co first reported a position in ARCT in Q2 2014 and held it in 2 quarters. The position peaked at $308K in Q2 2014. 28 funds tracked by Wall St. Rank hold ARCT as of Q4 2014.

  • Gilder Gagnon Howe & Co reported no remaining Arcturus Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 2,541 Arcturus Therapeutics shares in Q4 2014, an estimated $275K.
  • Gilder Gagnon Howe & Co first reported a position in Arcturus Therapeutics in Q2 2014 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Arcturus Therapeutics position peaked at $308K in Q2 2014.
  • 28 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2014.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2014, filed 13 Feb 2015.